Barclays PLC started coverage on shares of AveXis, Inc. (NASDAQ:AVXS) in a report released on Wednesday morning. The firm issued an overweight rating and a $124.00 target price on the stock.

A number of other research analysts have also weighed in on AVXS. Citigroup Inc. initiated coverage on shares of AveXis in a report on Tuesday, May 23rd. They issued a buy rating and a $90.00 target price for the company. Jefferies Group LLC reissued a buy rating and issued a $92.00 target price on shares of AveXis in a report on Thursday, May 25th. BMO Capital Markets reissued an outperform rating and issued a $95.00 target price on shares of AveXis in a report on Friday, June 16th. Chardan Capital set a $103.00 target price on shares of AveXis and gave the company a buy rating in a report on Sunday, June 18th. Finally, Zacks Investment Research raised shares of AveXis from a sell rating to a hold rating in a report on Thursday, July 13th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $99.75.

AveXis (NASDAQ:AVXS) opened at 93.665 on Wednesday. The firm’s market capitalization is $2.99 billion. AveXis has a one year low of $32.31 and a one year high of $99.45. The stock’s 50 day moving average is $92.16 and its 200-day moving average is $78.67.

AveXis (NASDAQ:AVXS) last posted its earnings results on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by $1.10. During the same quarter in the previous year, the firm earned ($0.68) EPS. On average, analysts anticipate that AveXis will post ($5.94) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/07/avexis-inc-avxs-now-covered-by-analysts-at-barclays-plc.html.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $91.52, for a total transaction of $162,905.60. Following the completion of the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at $162,905.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 5,340 shares of company stock valued at $474,637 over the last ninety days. 18.60% of the stock is owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Botty Investors LLC purchased a new stake in shares of AveXis during the second quarter valued at $123,000. Quantbot Technologies LP purchased a new stake in shares of AveXis during the first quarter valued at $117,000. Ameritas Investment Partners Inc. boosted its stake in shares of AveXis by 331.0% during the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after purchasing an additional 1,622 shares during the period. Seven Bridges Advisors LLC boosted its stake in shares of AveXis by 49.4% during the second quarter. Seven Bridges Advisors LLC now owns 2,557 shares of the company’s stock valued at $210,000 after purchasing an additional 846 shares during the period. Finally, Amalgamated Bank purchased a new stake in shares of AveXis during the second quarter valued at $219,000. 94.71% of the stock is owned by hedge funds and other institutional investors.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Stock Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related stocks with our FREE daily email newsletter.